Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100PLCG
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥679.7bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥1.27T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥620.8bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥4.1bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥1.9bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥18.2bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.8bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥5.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥740.6bnat 2022-09-30Cons.Assets
Total assets¥702.4bnat 2022-03-31Cons.Assets
Total assets¥695.9bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥495.0bnat 2022-09-30Cons.Liabilities
Total liabilities¥461.1bnat 2022-03-31Cons.Liabilities
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets
Net assets / equity¥241.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥240.7bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥102.1bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥94.3bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.1bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥88.9bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥11.6bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥11.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥4.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥2.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥189.72021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.392021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.842021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥174.482021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥42.622021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.3%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio34.5%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥654.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥631.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥708.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥679.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥4.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥996m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2021-04-01 → 2021-09-30¥45.5bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2021-04-01 → 2021-09-30¥45.4bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥5m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2021-04-01 → 2021-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2021-04-01 → 2021-09-30¥819m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2021-04-01 → 2021-09-30¥312m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2021-04-01 → 2021-09-30¥597.0bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2021-04-01 → 2021-09-30¥572.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥24.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥2.7bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥2.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥667m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥100m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥649.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥620.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 580
ItemContextValueUnit
Impairment loss ope cfPrior1YTDDuration12000000JPY
Impairment loss ope cfCurrentYTDDuration26000000JPY
Amortization of goodwill ope cfPrior1YTDDuration173000000JPY
Amortization of goodwill ope cfCurrentYTDDuration149000000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration39000000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration27000000JPY
Increase decrease in provision for sales returns ope cfPrior1YTDDuration-227000000JPY
Increase decrease in provision for sales returns ope cfCurrentYTDDuration－JPY
Increase decrease in provision for bonuses ope cfPrior1YTDDuration223000000JPY
Increase decrease in provision for bonuses ope cfCurrentYTDDuration121000000JPY
Increase decrease in provision for directors bonuses ope cfPrior1YTDDuration-55000000JPY
Increase decrease in provision for directors bonuses ope cfCurrentYTDDuration-32000000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration299000000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-98000000JPY
Interest and dividends income ope cfPrior1YTDDuration-854000000JPY
Interest and dividends income ope cfCurrentYTDDuration-774000000JPY
Interest expenses ope cfPrior1YTDDuration38000000JPY
Interest expenses ope cfCurrentYTDDuration39000000JPY
Loss gain on sales and retirement of noncurrent assets ope cfPrior1YTDDuration-5000000JPY
Loss gain on sales and retirement of noncurrent assets ope cfCurrentYTDDuration-35000000JPY
Loss gain on sales and valuation of investment securities ope cfPrior1YTDDuration-281000000JPY
Loss gain on sales and valuation of investment securities ope cfCurrentYTDDuration-7000000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration-3456000000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration-24070000000JPY
Decrease increase in inventories ope cfPrior1YTDDuration796000000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-1891000000JPY
Decrease increase in other assets ope cfPrior1YTDDuration-4294000000JPY
Decrease increase in other assets ope cfCurrentYTDDuration-3220000000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration4890000000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration36716000000JPY
Increase decrease in other liabilities ope cfPrior1YTDDuration5482000000JPY
Increase decrease in other liabilities ope cfCurrentYTDDuration2248000000JPY
Increase decrease in accrued consumption taxes ope cfPrior1YTDDuration1062000000JPY
Increase decrease in accrued consumption taxes ope cfCurrentYTDDuration-1384000000JPY
Other loss gain ope cfPrior1YTDDuration-2184000000JPY
Other loss gain ope cfCurrentYTDDuration-2605000000JPY
Subtotal ope cfPrior1YTDDuration9991000000JPY
Subtotal ope cfCurrentYTDDuration14140000000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration848000000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration777000000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-38000000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-36000000JPY
Income taxes paid ope cfPrior1YTDDuration-1441000000JPY
Income taxes paid ope cfCurrentYTDDuration-6348000000JPY
Other net ope cf subtotalPrior1YTDDuration2232000000JPY
Other net ope cf subtotalCurrentYTDDuration2160000000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration11593000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration10693000000JPY
Payments into time deposits inv cfPrior1YTDDuration-673000000JPY
Payments into time deposits inv cfCurrentYTDDuration-668000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass